These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Capecitabine for treating head and neck cancer. Iqbal H; Pan Q Expert Opin Investig Drugs; 2016 Jul; 25(7):851-9. PubMed ID: 27144283 [TBL] [Abstract][Full Text] [Related]
25. Human pluripotent stem cell-derived cardiomyocyte based models for cardiotoxicity and drug discovery. Zhao Y; Korolj A; Feric N; Radisic M Expert Opin Drug Saf; 2016 Nov; 15(11):1455-1458. PubMed ID: 27560951 [No Abstract] [Full Text] [Related]
26. Oromandibular dystonia: a serious side effect of capecitabine. van Pelt-Sprangers MJ; Geijteman EC; Alsma J; Boere IA; Mathijssen RH; Schuit SC BMC Cancer; 2015 Mar; 15():115. PubMed ID: 25850956 [TBL] [Abstract][Full Text] [Related]
27. Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment. Molteni LP; Rampinelli I; Cergnul M; Scaglietti U; Paino AM; Noonan DM; Bucci EO; Gottardi O; Albini A Breast J; 2010; 16 Suppl 1():S45-8. PubMed ID: 21050310 [TBL] [Abstract][Full Text] [Related]
28. Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial. He Y; Liu P; Zhang Y; Deng X; Meng W; Wei M; Yang T; Wang Z; Qiu M Trials; 2015 May; 16():238. PubMed ID: 26021722 [TBL] [Abstract][Full Text] [Related]
29. Capecitabine in locally advanced anal cancer, do we need randomised evidence? Chong LC; Healey T; Michele T; Price TJ Expert Rev Anticancer Ther; 2017 May; 17(5):411-416. PubMed ID: 28277833 [TBL] [Abstract][Full Text] [Related]
31. Fixed Drug Eruption Late in the Course of Capecitabine Therapy. Del Rosario M; Tsai H; Dasanu CA Conn Med; 2016 Apr; 80(4):223-5. PubMed ID: 27265926 [TBL] [Abstract][Full Text] [Related]
33. Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods. Bourmaud A; Henin E; Tinquaut F; Regnier V; Hamant C; Colomban O; You B; Ranchon F; Guitton J; Girard P; Freyer G; Tod M; Rioufol C; Trillet-Lenoir V; Chauvin F BMC Res Notes; 2015 Jul; 8():291. PubMed ID: 26142140 [TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study. Akgun Z; Saglam S; Yucel S; Gural Z; Balik E; Cipe G; Yildiz S; Kilickap S; Okyar A; Kaytan-Saglam E Cancer Chemother Pharmacol; 2014 Oct; 74(4):751-6. PubMed ID: 25102935 [TBL] [Abstract][Full Text] [Related]
35. Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer. Lu NN; Jin J; Wang SL; Wang WH; Song YW; Liu YP; Ren H; Fang H; Liu XF; Yu ZH; Li YX PLoS One; 2015; 10(4):e0124601. PubMed ID: 25915948 [TBL] [Abstract][Full Text] [Related]
36. Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. Hong JY; Park YH; Choi MK; Jung HA; Lee SJ; Ahn JS; Im YH Clin Breast Cancer; 2015 Oct; 15(5):e287-92. PubMed ID: 25997855 [TBL] [Abstract][Full Text] [Related]